Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
Effect of celecoxib on postoperative narcotic use and disease severity in patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis: a randomized controlled trial King Khalid University Hospital Ongoing Celecoxib 4 114809 King Khalid University Hospital (Riyadh) King Abdulaziz University Hospital (Riyadh)
EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40% Boehringer Ingelheim Ongoing BI 690517 , empagliflozin 3 1378-0020 King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
Effect of Probiotics “Psychobiotics” on Depression in Adults with Obesity and Metabolic Syndrome in Riyadh City King Khalid University Hospital Ongoing Winclove’s Ecologic® Barrier probiotics 3 E-23-7867 King Khalid University Hospital (Riyadh)
BalanceD-HF: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function AstraZeneca Ongoing balcinrenone/dapagliflozin 3 D6402C00012 King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh),King Fahad Medical City (Riyadh) ,King Khalid University Hospital (Riyadh)
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies CSL Behring LLC Ongoing HEMGENIX (etranacogene dezaparvovec) 3b CSL222_3005 King Faisal Specialist Hospital and Research Center (Riyadh)
REAL-WORLD, LONG-TERM DATA COLLECTION TO GAIN CLINICAL INSIGHTS INTO ROCHE OPHTHALMOLOGY PRODUCTS (VOYAGER STUDY)- COMPLETE Roche Ongoing Vabysmo 4 MR41927 King Abdulaziz Medical City NG (Jeddah)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) AstraZeneca Ongoing Ravulizumab 3 D928FC00001 King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam)
A Multicenter, Open-label, Single-arm, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE) Biogen Idec Research Limited Ongoing Litifilimab 3 230LE305 King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh)
SODium BICarbonate for Metabolic Acidosis in the Intensive Care Unit (SODa-BIC): A multicentre, randomised, double-blind clinical trial King Abdullah International Medical Research Center (KAIMRC) Ongoing SODIUM BICARBONATE 3 SCT23R/012/10 King Abdulaziz Medical City NG (Riyadh)
Real-World Evidence Study for the Safety and Effectiveness of Ribociclib in Combination with Hormonal Therapy in Patients with HR+/HER2- Advanced or Metastatic Breast Cancer in the Middle East Region Novartis Ongoing Ribociclib 4 CLEE011AIC King Faisal Specialist Hospital and Research Center (Riyadh)
View 11 - 20 From 741